Works matching IS 10781552 AND DT 2022 AND VI 28 AND IP 3
Results: 36
Evaluation of potential drug-drug interactions in cancer patients at a tertiary care hospital in Pakistan.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 618, doi. 10.1177/10781552221074629
- By:
- Publication type:
- Article
Ammonia level as a proxy of asparaginase inactivation in children: A strategy for classification of infusion reactions.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 551, doi. 10.1177/1078155221998738
- By:
- Publication type:
- Article
Evaluating Clostridioides difficile infection (CDI) treatment duration in hematology/oncology patients receiving concurrent non-CDI antibiotics.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 542, doi. 10.1177/1078155221998735
- By:
- Publication type:
- Article
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' quality of life: An Arabic version of the Functional Living Index-Emesis.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 535, doi. 10.1177/1078155221998447
- By:
- Publication type:
- Article
Patient-reported outcomes and digital literacy of patients treated in an oncology day hospital unit.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 530, doi. 10.1177/1078155221996041
- By:
- Publication type:
- Article
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 523, doi. 10.1177/1078155221996039
- By:
- Publication type:
- Article
Implementation, utilization, and evaluation of a pharmacist-driven romiplostim dosing service for patients with immune thrombocytopenia at a multisite cancer centre.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 613, doi. 10.1177/10781552211073763
- By:
- Publication type:
- Article
Cancer procoagulant inhibitors: New drugs for an old target.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 695, doi. 10.1177/10781552211073606
- By:
- Publication type:
- Article
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 686, doi. 10.1177/10781552211073575
- By:
- Publication type:
- Article
Role of clinical pharmacist in the palliative care of adults and elderly patients with cancer: A scoping review.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 664, doi. 10.1177/10781552211073470
- By:
- Publication type:
- Article
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 691, doi. 10.1177/10781552211073468
- By:
- Publication type:
- Article
Current molecular and therapeutic advances in liposarcoma, rhabdomyosarcoma, leiomyosarcoma, synovial sarcoma, and angiosarcoma.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 635, doi. 10.1177/10781552211073139
- By:
- Publication type:
- Article
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 646, doi. 10.1177/10781552211072468
- By:
- Publication type:
- Article
Addressing the Challenges of Novel Oncology and Hematology Treatments Across Sites of Care: Specialty Pharmacy Solutions.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 627, doi. 10.1177/10781552211072467
- By:
- Publication type:
- Article
Tyrosine kinase inhibitor nilotinib induced palmoplantar erythrodysesthesia: A rare case.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 763, doi. 10.1177/10781552211072465
- By:
- Publication type:
- Article
Nivolumab induced hypophysitis in an advanced RCC patient.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 759, doi. 10.1177/10781552211072212
- By:
- Publication type:
- Article
Carfilzomib-induced thrombotic microangiopathy. A case report.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 754, doi. 10.1177/10781552211067433
- By:
- Publication type:
- Article
Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 750, doi. 10.1177/10781552211067424
- By:
- Publication type:
- Article
Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 746, doi. 10.1177/10781552211066888
- By:
- Publication type:
- Article
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 740, doi. 10.1177/10781552211066073
- By:
- Publication type:
- Article
Refractory cytokine release reaction to Nivolumab: Following desensitization algorithms to optimize the management of drug hypersensitivity.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 736, doi. 10.1177/10781552211064312
- By:
- Publication type:
- Article
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 733, doi. 10.1177/10781552211062569
- By:
- Publication type:
- Article
Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 729, doi. 10.1177/10781552211062148
- By:
- Publication type:
- Article
Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 725, doi. 10.1177/10781552211060730
- By:
- Publication type:
- Article
Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 722, doi. 10.1177/10781552211060523
- By:
- Publication type:
- Article
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 717, doi. 10.1177/10781552211057867
- By:
- Publication type:
- Article
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 710, doi. 10.1177/10781552211057486
- By:
- Publication type:
- Article
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 703, doi. 10.1177/10781552211056856
- By:
- Publication type:
- Article
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 698, doi. 10.1177/10781552211055407
- By:
- Publication type:
- Article
Anticancer drug waste minimization and cost-saving study by using a closed-system transfer device for chemotherapy compounding.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 605, doi. 10.1177/10781552211008527
- By:
- Publication type:
- Article
Hypersensitivity reactions to paclitaxel: The Mexican experience of rapid desensitization.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 598, doi. 10.1177/10781552211008503
- By:
- Publication type:
- Article
A study to assess the impact of pharmaceutical care services to cancer patients in a tertiary care hospital.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 588, doi. 10.1177/10781552211005003
- By:
- Publication type:
- Article
Publication rates of hematology/oncology abstracts presented at major pharmacy association meetings.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 582, doi. 10.1177/10781552211004700
- By:
- Publication type:
- Article
Incidence of hypersensitivity reactions in patients on H1-receptor antagonists receiving oxaliplatin-based chemotherapy.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 577, doi. 10.1177/10781552211003958
- By:
- Publication type:
- Article
Older adults with colon cancer are not different from younger ones, but treated differently: Retrospective analysis from single centre.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 569, doi. 10.1177/10781552211002912
- By:
- Publication type:
- Article
Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 3, p. 560, doi. 10.1177/10781552211000113
- By:
- Publication type:
- Article